Compare PLTK & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLTK | ARDX |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2021 | 2014 |
| Metric | PLTK | ARDX |
|---|---|---|
| Price | $3.61 | $7.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $6.61 | ★ $11.55 |
| AVG Volume (30 Days) | 955.3K | ★ 4.3M |
| Earning Date | 02-26-2026 | 02-19-2026 |
| Dividend Yield | ★ 10.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $2,726,900,000.00 | $398,234,000.00 |
| Revenue This Year | $9.52 | $22.77 |
| Revenue Next Year | $2.76 | $28.02 |
| P/E Ratio | $16.18 | ★ N/A |
| Revenue Growth | 7.49 | ★ 58.12 |
| 52 Week Low | $3.31 | $3.21 |
| 52 Week High | $7.58 | $7.10 |
| Indicator | PLTK | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 33.37 | 73.45 |
| Support Level | $3.91 | $5.53 |
| Resistance Level | $4.10 | $6.40 |
| Average True Range (ATR) | 0.14 | 0.40 |
| MACD | -0.05 | 0.15 |
| Stochastic Oscillator | 4.84 | 85.52 |
Playtika Holding Corp is engaged in developing mobile games. Some of its games include Board Kings, House of Fun, Poker Heat, Slotomania, and Bingo Blitz. The company has built live game operations services and a proprietary technology platform to support its portfolio of games. It derives revenue from the sale of virtual items associated with online games. Geographically, the group has a business presence in the USA, EMEA, APAC, and Other regions of which key revenue is derived from the USA. It offers both Mobile and Web-based platforms.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.